Changes

no edit summary
Line 1,093: Line 1,093:  
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
 
|IgG4-related disease
 
|IgG4-related disease
Line 1,109: Line 1,109:  
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
 
|Unicentric Castleman disease
 
|Unicentric Castleman disease
Line 1,125: Line 1,125:  
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
 
|Idiopathic multicentric Castleman disease
 
|Idiopathic multicentric Castleman disease
Line 1,141: Line 1,141:  
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
 
|KSHV/HHV8-associated multicentric Castleman disease
 
|KSHV/HHV8-associated multicentric Castleman disease
Line 1,157: Line 1,157:  
|
 
|
 
|
 
|
|
+
|Multicentric Castleman Disease
 
|Sudha Arumugam, MD
 
|Sudha Arumugam, MD
|
+
|Complete
|
+
|01/24/2022
|
+
|Date completed by author: 01/24/2022
 
|-
 
|-
 
|B-lymphoblastic leukaemia/lymphoma
 
|B-lymphoblastic leukaemia/lymphoma